Anlotinib-associated pulmonary embolism in brainstem glioblastoma treatment: a case report
Anlotinib may cause PE and should be used with caution. Clinicians should close coagulation monitoring following anlotinib treatment, including D-dimer testing and imaging (eg, CT), to ensure prompt diagnosis and timely treatment for PE. This case highlights the critical need for vigilant PE monitoring and prompt management in GBM patients on anlotinib therapy.
Authors
- Jianglin Li (ORCID: https://orcid.org/0009-0007-2235-9355)
- Jia Zhou (ORCID: https://orcid.org/0000-0001-6357-9871)
- Yangyang Jiang (ORCID: https://orcid.org/0000-0002-5349-8354)
- Yongli Zhang (ORCID: https://orcid.org/0000-0001-7079-7973)
- Junwei Li (ORCID: https://orcid.org/0000-0002-2247-1239)
- Jun Zhao (ORCID: https://orcid.org/0000-0003-1464-7158)
- Shan Wu (ORCID: https://orcid.org/0000-0002-5849-3173)
- Ke-Jun Qu
Institutions
- Jinan University (CN)
- Southern University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-09
- DOI
- https://doi.org/10.3389/fonc.2025.1526337
- Citations
- 3
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56